Literature DB >> 23319179

High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.

Manij Patel1, Angela M Giddings, John Sechelski, John C Olsen.   

Abstract

BACKGROUND: A limitation to efficient lentivirus-mediated airway gene transfer is the lack of receptors to commonly used viral envelopes on the luminal surface of airway epithelia. The use of viral envelopes with natural tropism to the airway could be useful for overcoming this limitation.
METHODS: We investigated influenza hemagglutinin (HA) pseudotyped equine infectious anemia virus-derived lentiviral vector-mediated gene transfer to the airway epithelium of adult and newborn mice. For these studies, high-titer vectors were delivered by intranasal administration. In addition, we tested the feasibility of vector re-dosing to the nasal airway.
RESULTS: Delivery of high-titer HA pseudotyped lentiviral vectors by nasal administration to newborn mouse pups or adult mice results in the efficient transduction of airway epithelial cells in the nose, trachea, and lungs. In the nose, vector expression was predominant in the respiratory epithelium and was not observed in the olfactory epithelium. In the trachea and large airways of the lung, approximately 46% and 40%, respectively, of surface epithelial cells could be transduced. The efficiency of re-dosing to the nasal airway of mice was found to be dependent of the age of the animal when the first dose is administered, as well as the length of time between doses.
CONCLUSIONS: A single intranasal dose of concentrated influenza HA-pseudotyped lentiviral vector is sufficient for efficient gene transfer to the airways of mice. This is a promising result that could lead to the development of effective gene transfer reagents for the treatment of cystic fibrosis and other human lung diseases.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319179      PMCID: PMC5300025          DOI: 10.1002/jgm.2695

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  46 in total

1.  Alterations in receptor binding properties of recent human influenza H3N2 viruses are associated with reduced natural killer cell lysis of infected cells.

Authors:  Rachel E Owen; Eriko Yamada; Catherine I Thompson; Louisa J Phillipson; Clare Thompson; Elizabeth Taylor; Maria Zambon; Helen M I Osborn; Wendy S Barclay; Persephone Borrow
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report.

Authors:  Bonnie W Ramsey; Susan Banks-Schlegel; Frank J Accurso; Richard C Boucher; Garry R Cutting; John F Engelhardt; William B Guggino; Christopher L Karp; Michael R Knowles; Jay K Kolls; John J LiPuma; Susan Lynch; Paul B McCray; Ronald C Rubenstein; Pradeep K Singh; Eric Sorscher; Michael Welsh
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

3.  Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression.

Authors:  S M K Buckley; S J Howe; V Sheard; N J Ward; C Coutelle; A J Thrasher; S N Waddington; T R McKay
Journal:  Gene Ther       Date:  2008-04-24       Impact factor: 5.250

4.  A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction.

Authors:  J R Dorin; R Farley; S Webb; S N Smith; E Farini; S J Delaney; B J Wainwright; E W Alton; D J Porteous
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

5.  Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect.

Authors:  G Wang; V Slepushkin; J Zabner; S Keshavjee; J C Johnston; S L Sauter; D J Jolly; T W Dubensky; B L Davidson; P B McCray
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

6.  Fetal gene transfer with lentiviral vectors: long-term in vivo follow-up evaluation in a rat model.

Authors:  Jaan Toelen; Christophe M Deroose; Rik Gijsbers; Veerle Reumers; Lourenço N Sbragia; Sofie Vets; Satish K Chitneni; Guy Bormans; Luc Mortelmans; Jan A Deprest; Zeger Debyser
Journal:  Am J Obstet Gynecol       Date:  2007-04       Impact factor: 8.661

7.  Gene delivery to airway epithelial cells in vivo: a direct comparison of apical and basolateral transduction strategies using pseudotyped lentivirus vectors.

Authors:  Karlea L Kremer; Kylie R Dunning; David W Parsons; Donald S Anson
Journal:  J Gene Med       Date:  2007-05       Impact factor: 4.565

8.  Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors.

Authors:  J P O'Rourke; H Hiraragi; K Urban; M Patel; J C Olsen; B A Bunnell
Journal:  Mol Ther       Date:  2003-05       Impact factor: 11.454

9.  Amino acid 226 in the hemagglutinin of H4N6 influenza virus determines binding affinity for alpha2,6-linked sialic acid and infectivity levels in primary swine and human respiratory epithelial cells.

Authors:  Allen C Bateman; Marc G Busch; Alexander I Karasin; Nicolai Bovin; Christopher W Olsen
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

10.  Luciferin detection after intranasal vector delivery is improved by intranasal rather than intraperitoneal luciferin administration.

Authors:  Suzanne M K Buckley; Steven J Howe; Ahad A Rahim; Hildegard Buning; Jenny McIntosh; Suet-Ping Wong; Andrew H Baker; Amit Nathwani; Adrian J Thrasher; Charles Coutelle; Tristan R McKay; Simon N Waddington
Journal:  Hum Gene Ther       Date:  2008-10       Impact factor: 5.695

View more
  22 in total

1.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

2.  S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.

Authors:  Ajit Chande; Emilia Cristiana Cuccurullo; Annachiara Rosa; Serena Ziglio; Susan Carpenter; Massimo Pizzato
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-01       Impact factor: 11.205

Review 3.  Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy.

Authors:  Ziying Yan; Zoe A Stewart; Patrick L Sinn; John C Olsen; Jim Hu; Paul B McCray; John F Engelhardt
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-12       Impact factor: 5.032

4.  Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro.

Authors:  Leiping Zeng; Yanxia Liu; Xammy Huu Nguyenla; Timothy R Abbott; Mengting Han; Yanyu Zhu; Augustine Chemparathy; Xueqiu Lin; Xinyi Chen; Haifeng Wang; Draven A Rane; Jordan M Spatz; Saket Jain; Arjun Rustagi; Benjamin Pinsky; Adrianna E Zepeda; Anastasia P Kadina; John A Walker; Kevin Holden; Nigel Temperton; Jennifer R Cochran; Annelise E Barron; Michael D Connolly; Catherine A Blish; David B Lewis; Sarah A Stanley; Marie F La Russa; Lei S Qi
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

5.  Generation of a bovine cell line for gene engineering using an HIV-1-based lentiviral vector.

Authors:  Nanami Morizako; Erika P Butlertanaka; Yuri L Tanaka; Honoka Shibata; Tamaki Okabayashi; Hirohisa Mekata; Akatsuki Saito
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

Review 6.  Smelling the roses and seeing the light: gene therapy for ciliopathies.

Authors:  Jeremy C McIntyre; Corey L Williams; Jeffrey R Martens
Journal:  Trends Biotechnol       Date:  2013-04-17       Impact factor: 19.536

7.  Lentiviral-mediated phenotypic correction of cystic fibrosis pigs.

Authors:  Ashley L Cooney; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Mallory R Stroik; Linda S Powers; Nick D Gansemer; David K Meyerholz; Michael J Welsh; David A Stoltz; Patrick L Sinn; Paul B McCray
Journal:  JCI Insight       Date:  2016-09-08

Review 8.  Gene Therapy for Acute Respiratory Distress Syndrome.

Authors:  Jing Liu; David A Dean
Journal:  Front Physiol       Date:  2022-01-17       Impact factor: 4.566

Review 9.  Advances in gene therapy for cystic fibrosis lung disease.

Authors:  Ziying Yan; Paul B McCray; John F Engelhardt
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 5.121

Review 10.  Pseudotype-based neutralization assays for influenza: a systematic analysis.

Authors:  George William Carnell; Francesca Ferrara; Keith Grehan; Craig Peter Thompson; Nigel James Temperton
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.